Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,073 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID, Coronavirus Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID Card Pilot Study to Detect Antibodies to SARS-CoV-2

NCT05196932
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 15, 2026, 11:59 PM EDT
Not yet recruiting Not applicable Interventional

Fareon Open Label Device Clinical Trial

NCT07600320
View directory record Official record
Conditions
Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
Interventions
Fareon device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional

Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19

NCT04619706
View directory record Official record
Conditions
COVID-19
Interventions
FSD201, Placebo, Standard of Care for Covid-19
Drug · Other
Lead sponsor
Quantum Biopharma
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Miami, Florida • St. Petersburg, Florida • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Not listed Not applicable Interventional

This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Medical™ Rapid Antigen Test Comparing the Antigen Rapid Test to RT-PCR

NCT05491993
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
Sky Medical™ Rapid Antigen Test
Diagnostic Test
Lead sponsor
Sky Medical Supplies & Equipments, LLC
Industry
Eligibility
7 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lake Worth, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational

Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients

NCT04682548
View directory record Official record
Conditions
Multiple Sclerosis, Covid19
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

NCT06734741
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza B
Interventions
COVID/Flu Detect™ Rapid Self-Test
Diagnostic Test
Lead sponsor
InBios International, Inc.
Industry
Eligibility
2 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Miami, Florida • Boise, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Convalescent Plasma to Stem Coronavirus (CSSC-001)

NCT04323800
View directory record Official record
Conditions
Coronavirus, Convalescence
Interventions
Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Whiteriver, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

NCT04880161
View directory record Official record
Conditions
Covid19
Interventions
Ampion, Placebo
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Saliva as Source of Detection for SARS-CoV-2

NCT04424446
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 15, 2026, 11:59 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

SARS-CoV-2 OTC At Home Test

NCT05553964
View directory record Official record
Conditions
COVID-19 Pandemic
Interventions
In Vitro
Diagnostic Test
Lead sponsor
3EO Health
Industry
Eligibility
2 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Sunrise, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Terminated No phase listed Observational

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

NCT05876377
View directory record Official record
Conditions
SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions
Pfizer-BioNTech COVID-19 mRNA vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational

SARS-CoV-2 Donor-Recipient Immunity Transfer

NCT04666025
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Diagnostic Laboratory Biomarker Analysis, Electronic Health Record Review, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 15, 2026, 11:59 PM EDT
Suspended Early Phase 1 Interventional

Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues

NCT06171152
View directory record Official record
Conditions
Multiple Sclerosis, Long COVID, Long Covid19, Obese, Obesity, Obesity, Morbid, Acute Leukemia in Remission
Interventions
Liraglutide Pen Injector [Saxenda], Medication Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 15, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19

NCT04362189
View directory record Official record
Conditions
COVID-19
Interventions
HB-adMSC, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 15, 2026, 11:59 PM EDT
Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions
Rejuveinix (RJX) Active Comparator, Placebo Comparator
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Houston, Texas • New Braunfels, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

NCT04860297
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Mesa, Arizona • San Diego, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

NCT04813796
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 15, 2026, 11:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19: Human Epidemiology and Response to SARS-CoV-2

NCT04375761
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Interventions
Collection of Biological Samples, Symptom and Exposure Surveys
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
5,599 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
20
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 15, 2026, 11:59 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

NCT04363450
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis, Healthcare Worker, Sars-CoV2, Hydroxychloroquine
Interventions
Hydroxychloroquine, Placebo
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Lafayette, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 15, 2026, 11:59 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

NCT04815018
View directory record Official record
Conditions
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
Interventions
Not listed
Lead sponsor
Pathnostics
Industry
Eligibility
60 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Delaware, Ohio • Granville, Ohio • Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 15, 2026, 11:59 PM EDT
Not listed No phase listed Observational

Long COVID-19 and MAB Study

NCT05508295
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
MultiCare Health System Research Institute
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Renal Impairment Study of PF-07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function.

NCT04909853
View directory record Official record
Conditions
Renal Impairment
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 15, 2026, 11:59 PM EDT
Completed Phase 2 Interventional

A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19

NCT04522830
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
BTL-TML-COVID, Placebo
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
40 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Draper, Utah
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 15, 2026, 11:59 PM EDT